Earnings Feed
Sign Up
Home/Filings/4/0001104659-14-009237
4//SEC Filing

Celator Pharmaceuticals Inc 4

Accession 0001104659-14-009237

CIK 0001327467operating
View on SEC.govCompany Profile

Filed

Feb 11, 7:00 PM ET

Accepted

Feb 12, 8:39 PM ET

Size

20.3 KB

Accession

0001104659-14-009237

Insider Transaction Report

Form 4
Period: 2014-02-06
Celator Pharmaceuticals IncCNCE
Morenstein Scott D
Director
Transactions
  • Other

    Common Stock

    2014-02-10−95,945→ 0 total(indirect: See Footnotes)
  • Other

    Common Stock

    2014-02-10+1,123,612→ 1,123,612 total(indirect: See Footnotes)
  • Other

    Warrant

    2014-02-06−467,358→ 0 total(indirect: See Footnotes)
    Exercise: $3.58Exp: 2020-04-29→ Common Stock (467,358 underlying)
  • Other

    Warrant

    2014-02-06+358→ 358 total
    Exercise: $3.58Exp: 2020-04-29→ Common Stock (358 underlying)
  • Other

    Common Stock

    2014-02-10−1,669,138→ 0 total(indirect: See Footnotes)
  • Other

    Common Stock

    2014-02-10+1,277→ 1,277 total
  • Other

    Warrant

    2014-02-06−26,864→ 0 total(indirect: See Footnotes)
    Exercise: $3.58Exp: 2020-04-29→ Common Stock (26,864 underlying)
  • Other

    Warrant

    2014-02-06+314,611→ 314,611 total(indirect: See Footnotes)
    Exercise: $3.58Exp: 2020-04-29→ Common Stock (314,611 underlying)
Footnotes (6)
  • [F1]Pursuant to the dissolution of Valence Advantage Life Science Fund II, LP. ("Fund II"), 1,669,138 shares of common stock and 467,358 warrants were distributed in kind to the partners of Fund II on a pro rata basis without the receipt of any additional consideration.
  • [F2]Valence Life Sciences GP II, LLC ("GP II") was the sole general partner of Fund II and is the sole general partner of Valence Advantage Life Sciences Side Fund II, LP ("Side Fund II") and Valence CDK SPV, L.P. ("CDK SPV"). In his capacity as an advisor to GP II, the reporting person may be deemed to beneficially own securities held by Fund II, Side Fund II and CDK SPV. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.
  • [F3]Side Fund II distributed 95,945 shares of common stock and 26,864 warrants in kind to its sole limited partner without the receipt of any additional consideration.
  • [F4]In connection with the transaction described in footnote 1, CDK SPV received 1,123,612 shares of common stock and 314,611 warrants.
  • [F5]In connection with the transaction described in footnote 1, the reporting person received 1,277 shares of common stock and 358 warrants.
  • [F6]The warrants are immediately exercisable.

Documents

1 file

Issuer

Celator Pharmaceuticals Inc

CIK 0001327467

→
Entity typeoperating

Related Parties

1
  • filerCIK 0001327467

Filing Metadata

Form type
4
Filed
Feb 11, 7:00 PM ET
Accepted
Feb 12, 8:39 PM ET
Size
20.3 KB
View on SEC.gov